<p>中国杭州，2025 年 12 月 24 日（GLOBE NEWSWIRE）-- WORK Medical Technology Group LTD（纳斯达克股票代码：WOK）（“WORK Medical” 或 “公司”），通过其子公司 Work（杭州）医疗器械有限公司及其在中国的子公司，今天宣布将按 1 比 100 的比例进行普通股的反向拆分（“反向拆分”）。公司的 A 类普通股将在 2025 年 12 月 29 日市场开盘时开始以拆分后的基础进行交易。公司的 A 类普通股将继续在纳斯达克资本市场以 “WOK” 符号交易，新的 CUSIP 号码为 G9767H125。</p>
<p>反向拆分已获得公司股东和公司董事会的批准，主要是为了保持符合纳斯达克市场规则 5550(a)(2) 的要求，该规则涉及公司 A 类普通股的最低出价价格的维持。</p>
<p>任何因反向拆分而产生的零碎股份将被向上舍入至下一个整数，且不会发行零碎股份。反向拆分对所有股东均有统一影响，不会改变任何股东在公司已发行普通股中的百分比权益，除非因零碎股份的舍入而产生的调整。</p>
<p>在反向拆分生效后，截至生效日期，公司已发行和流通的每一百股 A 类普通股将自动合并为一股 A 类普通股，而截至生效日期，公司已发行和流通的每一百股 B 类普通股将自动合并为一股 B 类普通股。</p>
<p><strong>关于 WORK Medical Technology Group LTD</strong></p>
<p>WORK Medical Technology Group LTD 通过其子公司 Work（杭州）医疗器械有限公司及其在中国的子公司，是一家医疗器械供应商，开发和制造 I 类和 II 类医疗器械，并通过在中国的运营子公司销售 I 类和 II 类一次性医疗器械。公司拥有多样化的产品组合，包括 21 种产品，涵盖定制和多功能口罩及其他医疗耗材。所有产品已在中国 34 个省级行政区域销售，其中 15 种产品已在全球 30 多个国家销售。公司获得了多项与质量相关的制造认证，并已向美国食品药品监督管理局注册了 17 种产品，允许其产品进入美国市场。有关更多信息，请访问公司网站：https://www.workmedtech.com/corporate。</p>
<p><strong><em>前瞻性声明</em></strong></p>
<p><em>本新闻稿包含前瞻性声明，包括根据 1995 年《私人证券诉讼改革法》安全港条款作出的声明。这些声明可能通过诸如 “旨在”、“预期”、“相信”、“可能”、“估计”、“期望”、“预测”、“目标”、“打算”、“可能”、“计划”、“可能的”、“潜在的”、“寻求”、“将会” 等词语或类似表达来识别，旨在识别前瞻性声明。本新闻稿中任何不是历史事实的声明可能被视为前瞻性声明。本新闻稿中的任何前瞻性声明仅基于公司截至本声明日期的当前预期、估计和预测，并受到可能导致实际结果与这些前瞻性声明中所列或暗示的结果显著不同的多种风险和不确定性的影响。尽管公司相信这些前瞻性声明中表达的预期是合理的，但无法保证这些预期会被证明是正确的，公司提醒投资者，实际结果可能与预期结果显著不同，并鼓励投资者审查可能影响其未来结果的其他因素，这些因素在公司提交给美国证券交易委员会的 20-F 表格年报和其他文件中列出。公司明确声明，除法律要求外，没有义务更新任何前瞻性声明。</em></p>
<p><strong>如需更多信息，请联系：</strong></p>
<p><strong>WORK Medical Technology Group LTD</strong></p>
<p>投资者关系部</p>
<p>电子邮件：ir@workmedtech.com</p>
<p><strong>Ascent Investor Relations LLC</strong></p>
<p>Tina Xiao</p>
<p>电话：+1-646-932-7242</p>
<p>电子邮件：investors@ascent-ir.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qUTROeU0zTXpNME5EazRJelV3TURFeU56UXhNUT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qUTROeU0zTXpNME5EazRJelV3TURFeU56UXhNUT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MzMwMTJhOTMtZjc1Zi00NTM1LTkyM2ItMWFhNDJjZWYwZGI5LTUwMDEyNzQxMS0yMDI1LTEyLTI0LWVu/tiny/WORK-Medical-Technology-Group-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MzMwMTJhOTMtZjc1Zi00NTM1LTkyM2ItMWFhNDJjZWYwZGI5LTUwMDEyNzQxMS0yMDI1LTEyLTI0LWVu/tiny/WORK-Medical-Technology-Group-.png"/></p>

<p>WORK Medical Technology Group LTD 宣布将于 2025 年 12 月 29 日实施 1 股换 100 股的反向股票拆分。此举旨在保持符合纳斯达克的最低报价规则。拆分后，A 类股票将以 “WOK” 为交易代码，并获得新的 CUSIP 号码。零碎股份将被向上取整。该拆分对所有股东均匀适用，不会改变他们的持股比例。WORK Medical 在中国及国际市场提供医疗设备</p>

<p>Hangzhou, China, Dec. 24, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that it will effect a reverse stock split of its ordinary shares on a 1-for-100 basis (the “Reverse Stock Split”). The Company’s Class A ordinary shares will begin trading on a post-split basis when the market opens on December 29, 2025. The Company’s Class A ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol “WOK,” with a new CUSIP number G9767H125.</p>
<div class="lb-trans"><p>中国杭州，2025 年 12 月 24 日（GLOBE NEWSWIRE）-- WORK Medical Technology Group LTD（纳斯达克股票代码：WOK）（“WORK Medical” 或 “公司”），通过其子公司 Work（杭州）医疗器械有限公司及其在中国的子公司，今天宣布将按 1 比 100 的比例进行普通股的反向拆分（“反向拆分”）。公司的 A 类普通股将在 2025 年 12 月 29 日市场开盘时开始以拆分后的基础进行交易。公司的 A 类普通股将继续在纳斯达克资本市场以 “WOK” 符号交易，新的 CUSIP 号码为 G9767H125。</p>
</div><p>The Reverse Stock Split has been approved by the Company’s shareholders and the Company’s board of directors, and is being effectuated primarily to maintain compliance with Nasdaq Marketplace Rule 5550(a)(2) relating to the maintenance of the minimum bid price per share of the Company’s Class A ordinary shares.</p>
<div class="lb-trans"><p>反向拆分已获得公司股东和公司董事会的批准，主要是为了保持符合纳斯达克市场规则 5550(a)(2) 的要求，该规则涉及公司 A 类普通股的最低出价价格的维持。</p>
</div><p>Any fractional shares that would have otherwise resulted from the Reverse Stock Split will be rounded up to the next whole number and no fractional shares will be issued. The Reverse Stock Split affects all shareholders uniformly and will not alter any shareholder’s percentage interest in the Company’s outstanding ordinary shares, except for adjustments that may result from the rounding up of fractional shares.</p>
<div class="lb-trans"><p>任何因反向拆分而产生的零碎股份将被向上舍入至下一个整数，且不会发行零碎股份。反向拆分对所有股东均有统一影响，不会改变任何股东在公司已发行普通股中的百分比权益，除非因零碎股份的舍入而产生的调整。</p>
</div><p>Upon the effectiveness of the Reverse Stock Split, every one hundred shares of the Company’s issued and outstanding Class A ordinary shares as of the effective date will automatically be combined into one Class A ordinary share, and every one hundred shares of the Company’s issued and outstanding Class B ordinary shares as of the effective date will automatically be combined into one Class B ordinary share.</p>
<div class="lb-trans"><p>在反向拆分生效后，截至生效日期，公司已发行和流通的每一百股 A 类普通股将自动合并为一股 A 类普通股，而截至生效日期，公司已发行和流通的每一百股 B 类普通股将自动合并为一股 B 类普通股。</p>
</div><p><strong>About WORK Medical Technology Group LTD</strong></p>
<div class="lb-trans"><p><strong>关于 WORK Medical Technology Group LTD</strong></p>
</div><p>WORK Medical Technology Group LTD, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, is a supplier of medical devices that develops and manufactures Class I and II medical devices and sells Class I and II disposable medical devices through operating subsidiaries in China. The Company has a diverse product portfolio comprising 21 products, including customized and multifunctional masks and other medical consumables. All the products have been sold in 34 provincial-level administrative regions in China, with 15 of them sold in more than 30 countries worldwide. The Company has received a number of quality-related manufacturing designations and has registered 17 products with the U.S. Food and Drug Administration allowing their products to enter the U.S. market. For more information, please visit the Company’s website: https://www.workmedtech.com/corporate.</p>
<div class="lb-trans"><p>WORK Medical Technology Group LTD 通过其子公司 Work（杭州）医疗器械有限公司及其在中国的子公司，是一家医疗器械供应商，开发和制造 I 类和 II 类医疗器械，并通过在中国的运营子公司销售 I 类和 II 类一次性医疗器械。公司拥有多样化的产品组合，包括 21 种产品，涵盖定制和多功能口罩及其他医疗耗材。所有产品已在中国 34 个省级行政区域销售，其中 15 种产品已在全球 30 多个国家销售。公司获得了多项与质量相关的制造认证，并已向美国食品药品监督管理局注册了 17 种产品，允许其产品进入美国市场。有关更多信息，请访问公司网站：https://www.workmedtech.com/corporate。</p>
</div><p><strong><em>Forward-Looking Statements</em></strong></p>
<div class="lb-trans"><p><strong><em>前瞻性声明</em></strong></p>
</div><p><em>This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Any forward-looking statements in this press release are based on the Company’s current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results set forth in the Company’s annual report on Form 20-F and other documents filed by the Company with the U.S. Securities and Exchange Commission. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.</em></p>
<div class="lb-trans"><p><em>本新闻稿包含前瞻性声明，包括根据 1995 年《私人证券诉讼改革法》安全港条款作出的声明。这些声明可能通过诸如 “旨在”、“预期”、“相信”、“可能”、“估计”、“期望”、“预测”、“目标”、“打算”、“可能”、“计划”、“可能的”、“潜在的”、“寻求”、“将会” 等词语或类似表达来识别，旨在识别前瞻性声明。本新闻稿中任何不是历史事实的声明可能被视为前瞻性声明。本新闻稿中的任何前瞻性声明仅基于公司截至本声明日期的当前预期、估计和预测，并受到可能导致实际结果与这些前瞻性声明中所列或暗示的结果显著不同的多种风险和不确定性的影响。尽管公司相信这些前瞻性声明中表达的预期是合理的，但无法保证这些预期会被证明是正确的，公司提醒投资者，实际结果可能与预期结果显著不同，并鼓励投资者审查可能影响其未来结果的其他因素，这些因素在公司提交给美国证券交易委员会的 20-F 表格年报和其他文件中列出。公司明确声明，除法律要求外，没有义务更新任何前瞻性声明。</em></p>
</div><p><strong>For more information, please contact:</strong></p>
<div class="lb-trans"><p><strong>如需更多信息，请联系：</strong></p>
</div><p><strong>WORK Medical Technology Group LTD</strong></p>
<div class="lb-trans"><p><strong>WORK Medical Technology Group LTD</strong></p>
</div><p>Investor Relations Department</p>
<div class="lb-trans"><p>投资者关系部</p>
</div><p>Email: ir@workmedtech.com</p>
<div class="lb-trans"><p>电子邮件：ir@workmedtech.com</p>
</div><p><strong>Ascent Investor Relations LLC</strong></p>
<div class="lb-trans"><p><strong>Ascent Investor Relations LLC</strong></p>
</div><p>Tina Xiao</p>
<div class="lb-trans"><p>Tina Xiao</p>
</div><p>Phone: +1-646-932-7242</p>
<div class="lb-trans"><p>电话：+1-646-932-7242</p>
</div><p>Email: investors@ascent-ir.com</p>
<div class="lb-trans"><p>电子邮件：investors@ascent-ir.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qUTROeU0zTXpNME5EazRJelV3TURFeU56UXhNUT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxNjQ4NyM3MzM0NDk4IzUwMDEyNzQxMQ=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MzMwMTJhOTMtZjc1Zi00NTM1LTkyM2ItMWFhNDJjZWYwZGI5LTUwMDEyNzQxMS0yMDI1LTEyLTI0LWVu/tiny/WORK-Medical-Technology-Group-.png" alt="" original-src="https://ml.globenewswire.com/media/MzMwMTJhOTMtZjc1Zi00NTM1LTkyM2ItMWFhNDJjZWYwZGI5LTUwMDEyNzQxMS0yMDI1LTEyLTI0LWVu/tiny/WORK-Medical-Technology-Group-.png"/></p>

WORK Medical Technology Group LTD 宣布将进行 1 股合并为 100 股的反向股票分割，该措施将于2025年12月29日生效 | WOK 股票新闻